A Study to Assess the Long-Term Safety of Tacrolimus Cream in the Treatment of Psoriasis

Astellas Pharma Inc658 enrolled

Overview

A study to assess the long-term safety of tacrolimus cream in the treatment of psoriasis

A long-term, open label, non-comparative, multi-center study to evaluate the safety of tacrolimus cream-B 0.1% in treating the signs and symptoms of psoriasis.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

658

Conditions

Psoriasis

Interventions

Tacrolimus CreamDRUG

Eligibility

Sex: ALLMin age: 12 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Clinical diagnosis of plaque psoriasis Exclusion Criteria: * Skin disorder other than plaque psoriasis in the areas to be treated. * Disease on only scalp

Locations (37)

Outcomes

Primary Outcomes

Safety

Time frame: 12 months

Secondary Outcomes

Efficacy

Time frame: 12 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Unnamed facility

Birmingham, Alabama, United States

Unnamed facility

Fresno, California, United States

Unnamed facility

Santa Monica, California, United States

Unnamed facility

Vista, California, United States

Unnamed facility

Jacksonville, Florida, United States

Unnamed facility

Miami, Florida, United States

Unnamed facility

Atlanta, Georgia, United States

Unnamed facility

Newnan, Georgia, United States

Unnamed facility

Boise, Idaho, United States

Unnamed facility

Chicago, Illinois, United States

...and 27 more locations